Holen Sie sich die Stockscreener-App
0.0933
13.13%
-0.0141
Handel nachbörslich:
.09
-0.0033
-3.54%
Schlusskurs vom Vortag:
$0.1074
Offen:
$0.1003
24-Stunden-Volumen:
2.35M
Relative Volume:
0.34
Marktkapitalisierung:
$1.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-0.018
EPS:
-5.1824
Netto-Cashflow:
$-18.40M
1W Leistung:
-11.65%
1M Leistung:
-42.09%
6M Leistung:
-91.11%
1J Leistung:
-98.77%
1-Tages-Spanne:
$0.0927
$0.1011
1-Wochen-Bereich:
$0.0927
$0.1189
52-Wochen-Spanne:
$0.0927
$7.56
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.0933 | 2.11M | 0 | -25.09M | -18.40M | -5.1824 |
VRTX
Vertex Pharmaceuticals Inc
|
483.33 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.42 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.56 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.92 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.62 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLDI|Calidi Biotherapeutics Inc|Price:0.109|Chg%:+0.009 - TradingKey
Calidi Biotherapeutics Presents New Data on Cytotoxicity - GlobeNewswire
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics Inc (CLDI) Cash Flow - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
TradingKey - TradingKey
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
Calidi Gains on Company Update - Baystreet.ca
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewswire
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Sahm
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
Calidi Announces Reverse Stk Split, Expected to Begin Trading on a 1-For-16 Split Adjusted Basis on July 31 - Moomoo
Calidi shareholders will get one share for every 16 held - Stock Titan
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - Sahm
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
New lease could save Calidi Biotherapeutics (NYSE American: CLDI) $1.1M yearly - Stock Titan
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi lures new finance chief with 100,000 stock options - Stock Titan
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
CLDI Q4 2025 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue PhaseTech Earnings Analysis - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Growth Report - dars.gov.et
Calidi Biotherapeutics (CLDI) director Sanders Corazon files initial Form 3 - Stock Titan
CLDI Q4 2025 Earnings: EPS Surprises with 73.6% Beat as Clinical Pipeline AdvancesAnalyst Consensus Shift - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-than-expected loss boosts shares by 8.88%Low Growth Earnings - dars.gov.et
Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Sahm
Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan
Calidi Biotherapeutics unveils promising data o... - Pluang
Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 8K Calidi Biotherapeutics Inc For: 23 June - Investing.com UK
Calidi Biotherapeutics Expands Board With New Independent Director - TipRanks
Calidi Biotherapeutics Appoints Industry Veteran Corsee Sanders, Ph.D., to Board of Directors to Advance RedTail Platform and CLD-401 Clinical Development – Minichart - Minichart
Calidi Biotherapeutics appoints Corsee Sanders to board - Investing.com
Industry veteran Corsee Sanders joins Calidi Biotherapeutics (CLDI) board and Audit Committee - Stock Titan
Calidi Biotherapeutics appoints Corsee Sanders to board By Investing.com - Investing.com UK
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - The Manila Times
Press Release: Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Moomoo
Calidi Biotherapeutics Appoints Former Genentech/Roche and - GlobeNewswire
Calidi adds former Genentech and Roche executive to board - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Calidi Biotherapeutics (CLDI) Surges 11%: Micro-Cap Biotech Tests Key Resistance at $0.18PCR Spike - dars.gov.et
Calidi Biotherapeutics, Inc. Files Form 8-K with SEC: Key Corporate Details, Stock Info & NYSE American Listing - Minichart
CLDI News | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics Stockholders Approve Key Governance Measures - TipRanks
Calidi Biotherapeutics (CLDI) stockholders back all proposals at 2026 annual meeting - Stock Titan
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Calidi Biotherapeutics Inc-Aktie (CLDI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schoeneck James A | Director |
Aug 21 '25 |
Buy |
2.00 |
75,000 |
150,000 |
76,134 |
| Poma Eric E | Chief Executive Officer |
Aug 21 '25 |
Buy |
2.00 |
25,000 |
50,000 |
25,000 |
| Leftwich Scott | Director |
Aug 21 '25 |
Buy |
2.00 |
125,000 |
250,000 |
130,650 |
| Jackson Andrew C. | Chief Financial Officer |
Aug 21 '25 |
Buy |
2.00 |
2,500 |
5,000 |
2,500 |
0.54%
2.87%
Kapitalisierung:
|
Volumen (24h):